Singapore pharma on recovery path after dismal 2017

The pharmaceutical sector is the No. 2 contributor to the Singapore's manufacturing output and accounts for 3 per cent of its gross domestic product.
The pharmaceutical sector is the No. 2 contributor to the Singapore's manufacturing output and accounts for 3 per cent of its gross domestic product. PHOTO: ST FILE

Singapore's pharmaceutical business, among the pillars of the city-state's manufacturing sector, is set to return to strength this year as big global drugmakers ramp up output and advance automation at their production sites across the country.

A recovery from a dismal 2017, which marked the sector's worst contraction in two decades, would underpin Singapore's economic growth.

The pharmaceutical sector is the No. 2 contributor to the country's manufacturing output and accounts for 3 per cent of its gross domestic product.

The sector will see a "robust" 2018, Singapore's Economic Development Board (EDB) told Reuters.

"The opening of new sites like AbbVie's biologics manufacturing facility and the ramp-up of others, including Amgen and Novartis, reflect strong fundamentals... we expect the manufacturing activity to remain robust for 2018," said Ms Ho Weng Si, director of biomedical sciences for EDB.

"Outlook for the industry as a whole remains positive for the next few years," she added, citing the pace of new drug approvals by the US Food and Drug Administration that hit a 21-year high last year.

Singapore is well placed to benefit from this uptick in approvals as it hosts facilities of eight of the world's top 10 drugmakers - such as Roche, GlaxoSmithKline, Pfizer and Sanofi.

Sanofi, which in Singapore mainly produces ingredients for blood-thinning drugs shipped globally, told Reuters it expects production "to be relatively stable to slightly increasing in coming years" as it invests to upgrade capacity.

A quarterly EDB survey of the manufacturing sector shows the pharmaceutical industry is the most optimistic about production over January-March, with a net weighted balance of 56 per cent of firms expecting output to rise from the preceding three months.

Ms Ho and the survey did not provide a specific forecast.

Data shows pharmaceutical production fell in January, albeit at a milder pace, and rose 15.2 per cent from a year ago in February, bringing gains so far this year to about 7 per cent. Output shrank 15.6 per cent last year, the largest annual contraction since at least 1993.

Singapore's pharmaceutical output has risen more than threefold since the start of this century, with the sector generating $17 billion worth of products last year.

The outlook for recovery, however, is not free of headwinds. Pharmaceutical output is inherently volatile as production happens in batches, which can take anywhere from a few days to weeks to make.

But due to advancements in technology, industry players are hoping to achieve more consistent production levels.

GSK, which has been manufacturing in Singapore for nearly 50 years, has been pioneering a technology called continuous manufacturing where instead of making products in batches, materials are constantly added and products removed.

Last year, for the first time, products were commercially made using this technology.

"The pharma industry has to progress on the technology front... to ensure we increase productivity," said Mr Lim Hock Heng, a site director in Singapore for GSK.

Mundipharma hopes to start commercial production of antiseptics at its new plant in Singapore as early as the fourth quarter of next year - which, according to CEO Raman Singh, "will be the most automated plant in the world compared to any other competitors".

REUTERS

A version of this article appeared in the print edition of The Straits Times on March 27, 2018, with the headline 'S'pore pharma on recovery path after dismal 2017'. Print Edition | Subscribe